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Ubiquitously expressed calpains are Ca2-dependent,
intracellular cysteine proteases comprising a large cat-
alytic subunit (domains DI–DIV) and a noncovalently
bound small regulatory subunit (domains DV and DVI).
It is unclear whether Ca2-induced calpain activation is
followed by subunit dissociation or not. Here, we have
applied advanced fluorescence microscopy techniques
to study calpain subunit interactions in living cells us-
ing recombinant calpain subunits or domains fused to
enhanced cyan and enhanced yellow fluorescent re-
porter proteins. All of the overexpressed variants of the
catalytic subunit (DI-IV, DI-III, and DI-IIb) were active
and Ca2-dependent. The intact large subunit, but not
its truncated variants, associates with the small subunit
under resting and ionomycin-activated conditions. All
of the variants were localized in cytoplasm and nuclei,
except DI-IIb, which accumulates in the nucleus and in
nucleoli as shown by microscopy and cell fractionation.
Localization studies with mutated and chimeric vari-
ants indicate that nuclear targeting of the DI-IIb variant
is conferred by the two N-terminal helices of DI. Only
those variants that contain DIII migrated to membranes
upon the addition of ionomycin, suggesting that DIII is
essential for membrane targeting. We propose that in-
tracellular localization and in particular membrane tar-
geting of activated calpain, but not dissociation of its
intact subunits, contribute to regulate its proteolytic
activity in vivo.
Calpains are intracellular cysteine endopeptidases (clan CA)
requiring Ca2 ions for activity. The family members can be
classified as typical calpains, which are further divided into
ubiquitous and tissue-specific calpains, and atypical calpains
(reviewed in Ref. 1). Ubiquitous calpains are heterodimers
(molecular mass, 110 kDa) made up of a catalytic (molecular
mass, 80 kDa; 80K) and a common regulatory (molecular
mass, 30 kDa; 30K) subunit (2, 3). Two calpain isoforms are
known that share about 62% identical residues of their cata-
lytic subunits but differ in the Ca2 concentrations required for
activation in vitro; although -calpain is activated by 5–50 M
Ca2, m-calpain requires 0.2–1 mM Ca2 concentrations for
activation (4). Calpain activity is regulated in vivo by phospho-
rylation (5) and by the endogenous intracellular inhibitor, cal-
pastatin (6). The latter are widely distributed heat-stable pro-
teins acting specifically on calpains in vitro in the presence of
Ca2 (7). In addition, calpain inhibition by kininogen domain II
(8) and growth arrest-specific factor 2 (9) has been reported.
Upon exposure to Ca2, ubiquitous calpains undergo in vitro
limited autolysis of both subunits, which reduces Ca2 require-
ment for activity (10). Following initial autolysis at the N
terminus of both subunits, further degradation of the large
subunit eventually leads to a loss of enzymatic activity (11).
Controversial hypotheses of the activation mechanism of cal-
pain in vivo and the role of Ca2 in this process have been
presented (1, 11, 12). Important open questions in this regard
are whether or not calpain activation results in dissociation of
the large and small subunits and the probable role of autolysis.
Recent crystal structures of full-length, Ca2-free rat and
human m-calpain (13, 14) confirmed that the catalytic subunit
is organized in four domains, termed DI–DIV; the 30K subunit
consists of domains DV and DVI (Fig. 1, A and F). Compared
with the structurally homologous papain, subdomains DIIa
and DIIb are misplaced, with catalytic residues Cys105 and
His262 located about 10 Å apart. Moreover, the substrate bind-
ing cleft is disrupted and open, which is incompatible with
productive binding of peptide substrates. These features ex-
plain the inactivity of calpains in the absence of Ca2. The
crystal structure of Ca2-bound DII domain discloses two Ca2
ions that bridge subdomains IIa and IIb1 to form the catalyti-
cally competent active site, highlighting an important effect of
calcium for calpain activity (15). There are, however, additional
Ca2-binding sites with important roles for activity.
Domains DIV and DVI contain five EF hand motifs highly
similar to those of the major intracellular Ca2-binding pro-
tein, calmodulin. Accordingly, the first three N-terminal EF
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hands bind Ca2 (16). Calcium-mediated calpain activation
was therefore proposed to result from Ca2 binding to these
domains, mainly to the third EF hand in DIV. Ion binding is
expected to promote release of the N-terminal -helix that
anchors the catalytic and regulatory subunit, with concomitant
displacement of DIIa toward DIIb (17). An alternative hypoth-
esis points up the role of the synaptotagmin C2-like domain
DIII, which harbors several acidic residues within a prominent
solvent-exposed loop. This “acidic loop” is spatially adjacent to
DIIb and engages in electrostatic interactions with the latter
(14). It was suggested, therefore, that Ca2 binding to this loop
could release subdomain IIb to move toward IIa, thus allowing
formation of a functional catalytic center (the “electrostatic
switch” hypothesis). Furthermore, it was proposed that the
Ca2 coordination spheres might be only incompletely formed
by protein oxygen atoms and that additional ligands provided
by negatively charged head groups of acidic phospholipids com-
plete these coordination spheres. Indeed, acidic phospholipids
such as phosphorylated phosphatidyl inositols reduce the Ca2
concentration required for autolysis in vitro (10, 18, 19), and
mutation of the acidic residue Glu504 of m-calpain significantly
affects Ca2 sensitivity of the enzyme (13). Finally, DIII alone
binds Ca2 with an affinity comparable with that of DIV, which
is increased 2–10-fold upon the addition of liposomes (20).
Conversely, Ca2 significantly promotes phospholipid binding
in a similar manner as observed with the C2 synaptotagmin
domain. These findings suggest a connection between calpain
activation and membrane translocation (see e.g. Ref. 21).
In the light of these findings, we have decided to study
subcellular localization and subunit interactions of endogenous
calpains and overexpressed human -calpain subunits and sev-
eral engineered variants thereof, aiming to provide insight into
the calpain activation mechanism in vivo. Firstly, we have
followed the subcellular distribution of endogenous ubiquitous
human calpains and calpastatin under resting and Ca2-acti-
vated (ionomycin-induced) conditions. Next, we have overex-
pressed the active 80K subunit of human -calpain and its
truncated variants DI-III, DI-IIb, and DIII, N- or C-terminally
fused to ECFP,2 in COS 7 and in LCLC 103H cells. Co-expres-
sion with 30K chimeras that incorporate EYFP allowed us to
analyze the interactions between the 80K and 30K subunits in
vivo using fluorescence energy transfer techniques (FRET).
This technique is particularly suited to demonstrate intimate
(below 80 nm) contact between reaction partners. Recent pro-
gress in fluorescence microscopy has made it possible to apply
this technique to interaction analysis in living cells (22). At the
same time, overexpression of the 80K-EYFP chimera in cells
stably overexpressing a membrane marker, mem-ECFP, com-
bined with co-localization analysis (23) supported the mem-
brane association of this subunit. We provide evidence against
dissociation of calpain subunits upon activation in vivo. Both
endogenous and overexpressed calpain variants were localized
in the cytoplasm and/or nucleus of cells, respectively, except
DI-IIb, which accumulated in the nucleus and even in nucleoli.
Localization studies with five additional truncated or mutant
variants of the DI-IIb construct identify the N-terminal helices
of DI as a putative nuclear-targeting motif.
2 The abbreviations used are: ECFP, enhanced cyan fluorescent pro-
tein; AC27P, acetyl calpastatin 27-peptide; EYFP, enhanced yellow
fluorescent protein; FRET, fluorescence resonance energy transfer; Suc-
LLVY-amc, succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin.
FIG. 1. Calpain variants used in subcellular localization and subunit interaction studies. A–D, ribbon drawings of m-calpain
three-dimensional structure and variants studied in this work. B, 80K; C, DI-III; D, DI-IIb. The panels were prepared with SETOR using the
Protein Data Bank entry for human m-calpain (1DKV). Color labels of the domains are as follows: I, green; IIa, yellow; IIb, red; III, blue; IV,
gold-brown; V, orange-brown; and VI, orange. E, electrostatic surface potential of DI-IIb calculated with the GRASP software. Positively and
negatively charged surfaces are blue and red colored, respectively. F, summary of variants of human -calpain overexpressed in COS 7 and LCLC
103H cells. The asterisks indicate the positions of mutated amino acid residues.
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EXPERIMENTAL PROCEDURES
Materials—The plasmid vectors pECFP-C1, pECFP-N1, pEYFP-C1,
and pEYFP-N1 were purchased from Clontech; restriction endonucle-
ases and DNA modifying enzymes were from Roche Biochemicals and
New England Biolabs. Antibodies anti-peptide 80K and anti-peptide
76K were produced by Biogenes on request. Commercially available
antibodies used were anti-DII (804–051-R100, Alexis), anti-80K
(MAB3104, Chemicon), anti-30K (MAB3083, Chemicon), anti-calpasta-
tin (MA3–945, ABR), anti-living colors (8367–1, Clontech), and anti-
calpain (laboratory stock). The fluorogenic substrate Suc-LLVY-amc
was purchased from Bachem. The calpain inhibitor, AC27P, and iono-
mycin were from Sigma. All other reagents were of the highest purity
commercially available.
Plasmid Construction and Preparation—All of the variants of human
-calpain large subunit for expression in mammalian cells were con-
structed using as scaffold a self-prepared semi-synthetic gene,
pUC18_80K DNA, or a variant thereof with the active site residue
Cys115 mutated to alanine (pUC18_ [C115A]80K).3 Variants DI-IV
(Ser2–Ala711), DI-III (Ser2–Asp523), and DIII (Ile363–Gln527) were ob-
tained via PCR, using primers listed in Table I. The DNA for variant
DI-IIb (Ser2–Thr390) was obtained by digestion of pECFP_80K DNA
with the restriction enzymes EcoRI and SacII. The small subunit DNA
was amplified via PCR using as template a plasmid coding for the
His-tagged 30K subunit3 (Table I). The DNA fragments were subcloned
into the appropriate vectors, pECFP-N1 (80K-ECFP, [C115A]80K-
ECFP), pECFP-C1 (ECFP-80K, ECFP-[C115A]80K, ECFP-DI-III,
ECFP-DI-IIb, ECFP-DIII), pEYFP-N1 (30K-EYFP, 80K-EYFP, DI-III-
EYFP), and pEYFP-C1 (EYFP-30K), after digestion with the indicated
restriction enzymes (Table I). Competent TG1 cells were transformed
with the ligation mixtures, and the resulting isolated plasmids with the
correct sequences were used for further transfections. The variants
ECFP-[K20P]DI-IIb, ECFP-[R48P]DI-IIb, and ECFP-[R376A,R377A]-
DI-IIb were prepared via PCR using as template pECFP_DI-IIb DNA
according to the QuikChangeTM site-directed mutagenesis kit instruc-
tions (Stratagene) using the primers listed in Table II. Variants that
either lack the two N-terminal helices (ECFP-(Ser2–Leu55)DI-IIb) or
consist of these two helices fused to ECFP (ECFP-(Ser2–Leu55)) were
obtained by double-digesting pECFP_DI-IIb DNA with EcoRI/KpnI or
KpnI/BamHI, respectively, followed by ligation into pECFP-C1 digested
with the same pairs of enzymes. The identity of cloned DNAs was
verified by sequencing both DNA strands.
Cell Culture and Transfection—For routine cell culture RPMI 1640
medium (LCLC 103H cells, DSMZ ACC 384) or Dulbecco’s modified
Eagle’s medium (COS 7, ATCC CRL 1651) (Invitrogen) were supple-
mented with 10% fetal calf serum (Sigma), 0.6% L-glutamine (Invitro-
gen). Transfection was carried out using the FuGENE 6 Reagent (Roche
Molecular Biochemicals) according to the general protocol suggested by
the manufacturer. COS 7 and LCLC 103H cells transiently overex-
pressing the corresponding construct were used in this study. For
membrane targeting studies a LCLC 103H clone constitutively express-
ing the membrane marker mem-ECFP (Clontech) was transfected with
80K-EYFP and DI-III-EYFP DNAs. For localization experiments of
ECFP-DI-IIb and variants thereof, a LCLC 103H clone expressing
constitutively histone H2A coupled to EYFP was used. Histone H2A-
EYFP and mem-ECFP expressing cell clones of LCLC 103H were ob-
tained as described earlier (24).
Isolation and Analysis of Cytoplasmic Proteins—Cytoplasmic ex-
tracts from approximately 106 cells were prepared according to Ref. 25.
Briefly, pools of cells transfected with the corresponding constructs
were either kept untreated or incubated with the ionophore for 30 min
before cell lysis and fractionation. The protein content was assayed by
the bicinchoninic acid method (26). The samples were electrophoreti-
cally resolved on SDS-Tris-glycine (12.5%) gels, transferred to nitrocel-
lulose membranes (Schleicher & Schuell), and probed against the indi-
cated antibodies; the resulting complexes were detected with anti-
mouse or anti-rabbit horseradish peroxidase-linked IgG from New
England Biolabs using ECL (Amersham Pharmacia Biotech).
Immunoprecipitation—The cell lysates were preincubated with the
antibody anti-80K, bound to protein G-agarose (Roche Diagnostics), and
eluted according to Ref. 12. The immunoprecipitated proteins were
separated in SDS-Tris-glycine (12.5%) gels, transferred to nitrocellulose
membranes, and detected with anti-calpain, a polyclonal antibody that
recognizes both large and small calpain subunits.
Epifluorescence Microscopy—The cells were cultured on 4.2-cm-di-
ameter coverslips (Langenbrinck) or in Lab-Tec™ II cover glass cham-
bers (Nunc) and used for microscopical studies 24–72 h after transfec-
tion with the indicated constructs. Prior to observation, the coverslips
were mounted in perfusion chamber holders (PeCon) that were kept at
34–36 °C and 5% CO2 during observation. The microscope (Axiovert
S100 TV, Zeiss) was equipped with objectives Fluor 40/1.3 oil Ph2,
Apochromat 40/1.2 W korr, or Neofluar 63/1.25 oil Ph3, filter wheels,
and shutters (Ludl); Orca 4742–95 CCD camera (Hamamatsu), and
controlled by OpenLab software (Improvision). Filter systems for
ECFP, EYFP, and FRET were from Chroma Technologies (excitation
(Ex): 435/10 nm and 515/10 nm; single band: dichroic mirror (DM)ECFP
455 nm, emission (Em)ECFP 480/40 nm and DMEYFP 530 nm, EmEYFP
560/40 nm; doubleband: DMECFP 475 nm, EmECFP 470/30 nm, DMEYFP
556 nm, EmEYFP 555/40 nm; and FRET: DM 460 nm, Em 535/30 nm).
All of the observations were carried out in the corresponding growth
medium. The images were captured before and after the addition of
ionomycin to 2 M end concentration during 30 min in 5-min intervals.
To obtain optical section series a Piezo electric motor (Physical Instru-
ments) was used to drive the C-Apochromat 40 objective in appropri-
ate steps. The images were processed by deconvolution, and false color
look-up tables were applied to them for the final presentation. Co-
localization was analyzed by the respective Openlab™ software module,
which operates on a pixel-by-pixel comparison of pairs of images (23).
Immunocytofluorescence Detection of Endogenous Calpain and Cal-
pastatin—The cells were grown on glass coverslips and stained accord-
ing to Becton Dickinson Transduction Laboratories protocol using the
indicated antibodies. For fluorescence microscopy, the coverslips were
mounted on microscope slides with PermaFluor (Immunotech) and in-
spected in the microscope (LSM 410, Zeiss) equipped with the objective
Fluor 63/1.4 oil Ph2. The images were acquired using LSM410 software
version 3.95 (Zeiss). For cytoskeletal immunostaining (F-actin), the
cells were preincubated with ALEXA633-phalloidin (Molecular Probes).
The second antibodies used were ALEXA488 anti-mouse and anti-
rabbit (Molecular Probes), detected at excitation 488 nm, beam splitter
FT 488/543, and emission 515–525 nm. F-actin was visualized with the
same beam splitter at excitation 633 nm and emission 665 nm. The
image parameters were 512  512 pixels, pinhole 20.
Confocal Laser Scanning Microscopy—The cells were prepared as for
epifluorescence microscopy. The microscope (Leica TCS SP) was
equipped with objectives, Fluor 40/1.3 oil Ph2 and Neofluar 63/1.25 oil
Ph3, and the following filter sets: ExECFP 453 nm, EmECFP 495/60 nm;
ExEYFP 514 nm, EmEYFP 585/70 nm. The images were taken before and
3 D. Pfeiler, I. Assfalg-Machleidt, E. Bonzon, N. Gollmitzer, D. Gabri-
jelcic-Geiger, J. K. Gerber, H. Fritz, E. A. Auerswald, S. Gil-Parrado,
and W. Machleidt, manuscript in preparation.
TABLE I
Primers used for the construction of large and small subunit variants of human -calpain fused to ECFP and EYFP
Primera Sequence Variant
Forward primers
EcoRI 80K 5-CCG GAA TTC TGA TGT CGG AGG AGA TC-3 80K-ECFP, 80K-EYFP, [C115A]80K-
ECFP, ECFP-DI-III, DI-III-EYFP
HindIII_DIII 5-CCC AAG CTT CGA TGA TCC GCA AAT GGA ACA CCA-3 ECFP-DIII
BglII_30K 5-GGA AGA TCT ATG TTC CTG GTT AAC TCG TTC-3 30K-EYFP
Reverse primers
BamHI_80K 5-CGC GGA TCC TGC AAA CAT GGT CAG CTG-3 80K-ECFP, 80K-EYFP, [C115A]80K-
ECFP
BamHI_DIII 5-CGC GGA TCC TCA TTA CTG GTC ATC CAG CTC CAC AGT-3 ECFP-DI-III, DI-III-EYFP, ECFP-DIII
SmaI_30KHis 5-CCC CGG GAG TGA TGA TGA TGA TGA TGG GAA TAC ATA GTC
AGC TGC AG-3
30K-EYFP
a The name of the primer includes the DNA restriction enzyme used for cloning (in italics). The corresponding cleavage sites are also in italics.
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after the addition of 2 M ionomycin during 30 min in 5-min intervals.
The imaging parameters were 512  512 pixels, pinhole 1. Other
relevant parameters are given with the respective images. All of the
images were processed with a 3  3 median filter.
Calpain Activity in Living Cells—Calpain activity in living cells was
determined as previously described (27), using the fluorogenic sub-
strate Suc-LLVY-amc. The specificity of calpain cleavage was evaluated
by preincubating culture cells with 50 M AC27P (28) for 1 h before
treatment with 2 M ionomycin.
Measurement of Free Ca2 Concentrations—Free Ca2 concentra-
tions in COS 7 cells were determined before and after the addition of 2
M of ionomycin, as previously described (27).
RESULTS
Subcellular Localization of Endogenous Calpain and Cal-
pastatin by Immunocytofluorescence—The subcellular localiza-
tion of endogenous calpain and calpastatin was characterized
by immunocytofluorescence microscopy using the monoclonal
antibodies anti-DII (specific for -calpain large subunit resi-
dues Gly245–Phe265), anti-30K, and anti-calpastatin, respec-
tively. Prior to Ca2 mobilization, both calpain subunits and
calpastatin are homogenously distributed in the cytoplasm,
with a slight preponderance around the nuclear region (Fig. 2).
Also, calpastatin accumulated in the nuclei (Fig. 2C). After the
addition of ionomycin, fluorescence labeling caused by calpain
detection increased at cell membranes (Fig. 2, A and B),
whereas calpastatin did not relocalize to membranes under
calcium-stimulating conditions (Fig. 2C).
Overexpression of ECFP- and EYFP-fused Human -Calpain
Variants in COS 7 and LCLC 103H Cells—For expression in
mammalian cells, DNA fragments coding for the human -cal-
pain 80K subunit (residues Ser2–Ala711) or its truncated vari-
ants Ser2–Asp523 (DI-III), Ser2–Thr390 (DI-IIb), and Ile363–
Gln527 (DIII), as well as the active site mutant [C115A]80K
were ligated into vector pECFP-C1 to generate chimeric pro-
teins N-terminally extended with ECFP. DNAs coding for the
wild type and active site-mutated large subunit were ligated
into pECFP-N1 to produce variants C-terminally tagged with
ECFP, respectively. 80K and DI-III were also fused to the N
terminus of EYFP. Similarly, the 30K DNA was ligated into
pEYFP-C1 or pEYFP-N1 to allow expression of chimeric con-
structs with EYFP attached to the N or C terminus of the small
subunit, respectively (see Fig. 1F for a schematic representa-
tion of the variants).
First, we determined whether fusion of enhanced fluores-
cence protein at either terminus of the 80K calpain subunit
influences the protein expression level. LCLC 103H cells were
transfected with plasmids encoding for either the individual
large subunit (pECFP_80K, p80K_ECFP) or small subunit chi-
meras (p30K_EYFP and pEYFP_30K) or co-transfected with all
possible combinations of chimeric 80K and 30K constructs. The
cells were lysed 72 h after transfection, and the cytoplasmic
extracts were analyzed by Western blot using anti-DII antibody
(Fig. 3A). All of the variants were successfully overexpressed,
but the expression levels of variants in which ECFP is fused to
the N terminus of the 80K subunit were systematically lower
than those of the C-terminal fusions (Fig. 3A). The latter spe-
cies were therefore selected for subsequent cellular localization
studies. Of note, the 80K subunit of endogenous calpain was
also detected in mock transfected cells (Fig. 3A).
Intracellular Calcium Concentrations in COS 7 and LCLC
103H Cells—Addition of a calcium ionophore to cells leads to an
increase in the intracellular calcium concentration with con-
comitant generation of calpain activity (27, 29). Fura-2 meas-
urements of intracellular calcium concentrations were carried
out in living cells before and after addition of 2 M ionomycin.
In both cell lines, the addition of ionomycin caused a fast
transient increase (“burst”) in the intracellular Ca2 concen-
tration before equilibrium was reached (Fig. 3B). Interestingly,
we observed remarkable differences regarding (i) the peak val-
ues of intracellular Ca2 concentration (between 800 nM and
1.6 M in LCLC 103H cells (27), but only between 180 and 240
nM in COS 7 cells) and (ii) the intracellular Ca2 concentration
at equilibrium (180 nM in LCLC 103H cells (27) and 50 nM in
COS 7 cells) (Fig. 3B).
Calpain Activity in Living Cells—The fluorogenic peptide
substrate Suc-LLVY-amc (30) was used to investigate calpain
activity in vivo after calcium stimulation. The cells were
treated with 160 M Suc-LLVY-amc and 2 M ionomycin, and
fluorescence at 460 nm was measured in 5-min intervals for up
TABLE II
Primers used for the construction of ECFP-DI-IIb variants
Primer Sequencea Variant
K20_Forward 5-GCT CAG GTT CAG CCG CAG CGT GCT CGA GAA-3 K20P
K20_Reverse 5-TTC TCG AGC ACG CTG CGG CTG AAC CTG AGC-3 K20P
R48_Forward 5-GAA CAG CTG CGC GTA CCG TGC CTG CAG TCC-3 R43P
R48_Reverse 5-GGA CTG CAG GCA CGG TAC GCG CAG CTG TTC-3 R43P
R376/377_Forward 5-TCC CGT ACC ATC GCG GCG TGG AAC ACC ACC-3 R376A, R377A
R376/377_Reverse 5-GGT GGT GTT CCA CGC CGC GAT GGT ACG GGA-3 R376A, R377A
a Mutations are underlined.
FIG. 2. Differential subcellular localization of endogenous ubiquitous calpains and calpastatin by immunofluorescence. The cells
were permeated, fixed, and stained as explained under “Experimental Procedures.” Confocal laser scanning microscopy images were taken before
or after treatment with 2 M ionomycin as indicated. The cells were preincubated with anti-DII (A), anti-30K (B), or anti-calpastatin monoclonal
antibodies (C), as well as with phalloidin (A–C) to detect F-actin. Notice the nuclear localization of calpastatin in C. The arrows indicate membrane
association of the large and small subunit. The bars represent 12.5 m (A, upper panels), 25 m (A, lower panels, and C), and 40 m (B).
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to 1 h. We have previously shown that the addition of the
calcium ionophore results in an 2-fold increase in calpain
activity, which was specifically inhibited by AC27P (27). We
have now confirmed that calpain activity was stimulated by the
addition of ionomycin in both COS 7 (Fig. 3C) and LCLC 103H
cells (Fig. 3D), also in agreement with previous reports in other
cell lines (31–33). Furthermore, the cells overexpressing -cal-
pain chimeras that include the catalytic domain showed simi-
lar levels of Ca2-dependent activity as variants of full-length
80K. Calpain activities of these fusion proteins were4-fold (in
COS 7 cells) or 3-fold higher (in LCLC 103H cells) than those
of wild type and mock transfected cells. Most of the ionophore-
induced hydrolytic activity was inhibited by preincubation of
cells with the specific calpain inhibitor, 50 M AC27P (Fig. 3, C
and D), thus confirming that the observed activity results al-
most exclusively from calpain activation. No significant differ-
ences in activity were detected between cells co-expressing
large and small subunit variants and those transfected with
the large subunit chimeras alone. Interestingly, the cells that
exclusively overexpressed the small subunit variants showed
significantly higher hydrolytic activities than wild type and
mock transfected cells.
Subcellular Localization of Human -Calpain Variants and
Calpain Subunit Interactions—Epifluorescence microscopy
was used to study (i) the localization of overexpressed -calpain
subunits and truncated variants of the large subunit and (ii)
the interaction between large and small calpain subunits in
vivo. Both under resting and activated conditions (Fig. 4A), the
FIG. 3. Overexpressed chimeras of
human -calpain are Ca2-activable.
A, Western blots of cytoplasmic fraction of
cells expressing the indicated variants
probed with anti-DII antibody. The mo-
lecular masses of 80K-ECFP and ECFP-
80K (107 kDa) or the large subunit of
endogenous human -calpain (80 kDa)
are indicated with arrows. B, increase of
intracellular calcium concentration upon
ionomycin addition to COS 7 cells. The
cells were loaded with Fura-2 for 30 min
and then treated with 2 M ionomycin as
explained under “Experimental Proce-
dures.” The average calcium concentra-
tion in five different cells is represented
(black squares). C and D, calpain activity
in COS 7 (C) and LCLC 103H cells (D)
transiently overexpressing fluorescence-
tagged variants of human -calpain sub-
units. Relative increase of Suc-LLVY-amc
hydrolyzing activity compared with wild
type cells (activity  1, dotted lines) is
shown by black (for cells that were not
treated with AC27P) or white bars (cells
preincubated with 50 M AC27P), respec-
tively. The standard deviations of three
measurements are indicated (bars).
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80K and 30K subunits co-localized in the cytosol, as indicated
by the fluorescence (colored yellow-brown) observed upon exci-
tation with the FRET filter (Fig. 4A). Upon the addition of the
ionophore the two subunits seem to migrate together, mainly to
the plasma membrane (Fig. 4A, white arrows). In cells co-
expressing nonfused ECFP and EYFP, we observed uniform
patterns of cytoplasmic localization but no quenching of the
ECFP fluorescence either under resting or activated conditions
(data not shown), thus ruling out that the observed FRET
effects were due to unspecific interactions. These results were
corroborated by co-immunoprecipitation of the 30K and 80K
subunits under resting and Ca2-activated conditions (Fig.
4B). No FRET was observed in cells transiently co-expressing
truncated variants of -calpain large subunit fused to ECFP
and 30K-EYFP (data not shown), in agreement with the se-
verely reduced interaction interfaces after deletion of either the
C-terminal domains (chimeras of DI-III and DI-IIb) or both the
N- and C-terminal domains (DIII; compare Fig. 1, A–D).
Confocal laser scanning microscopy was further used to
study the intracellular localization and trafficking of the -cal-
pain subunits and of truncated variants thereof. Chimeras
80K-ECFP and 30K-EYFP homogenously co-localized in the
cytoplasm under resting conditions, without obvious accumu-
lation in subcellular organelles. Further, we could confirm
their migration to membranes upon the addition of ionomycin
(Fig. 5, A–C). Again, comparison of both fluorescence patterns
provides additional evidence that the two subunits co-localize
throughout (Fig. 5C). The migration of the small subunit var-
iant seems to occur in vesicle-like structures of about 1 m in
diameter (Fig. 5B). Whether the large subunit is included
within these structures is unknown, but co-localization of both
subunits throughout would point to its inclusion in these ves-
icles (see “Discussion”).
Overexpressed ECFP-DI-III was distributed homogenously
in the cytoplasm and within the nucleus (Fig. 5D). In this
figure, images corresponding to the same cell are shown at two
different levels (whole cell, upper panels; nucleus, lower panels)
to highlight the ionomycin-dependent migration of ECFP-DI-
III to both the plasma and nuclear membranes. In contrast,
overexpressed ECFP-DI-IIb was mainly observed in the cell
nucleus including the nucleoli, and this localization pattern did
not change after the addition of ionomycin (Fig. 5E).
To confirm the plasma membrane association of calpain or
its subunits, 80K and DI-III DNAs were fused to EYFP and
supertransfected into LCLC 103H clone cells constitutively
expressing a membrane marker, mem-ECFP. Fluorescence im-
age series were taken in the respective channels, processed by
deconvolution algorithms, and analyzed comparatively pixel-
by-pixel with a co-localization program. The result of this proc-
ess is given by a representative example of the 80K-EYFP
construct (Fig. 6); it clearly demonstrates the plasma mem-
brane association of the 80K subunit. Experiments conducted
with the DI-III construct had similar outcomes (data not
shown).
Subcellular Localization of Calpain Variants by Western Blot
Analysis—To further confirm the results obtained with micro-
scopic techniques, the relative distribution of calpain chimeras
in transfected LCLC 103H cells was assessed via Western blot
analysis. Equal amounts of cells (106) either untreated or in-
cubated with 2 M ionomycin were fractionated by centrifuga-
tion. The purity of isolated fractions was verified by measuring
a 15-fold higher activity of lactate dehydrogenase in the cy-
toplasmic than in the nuclear fractions (data not shown), indi-
cating a successful separation (34). Moreover, only the nuclear
but not the cytoplasmic fraction was stained by propidium
iodide (data not shown).
The separated fractions were analyzed by Western blot using
either anti-DII or a polyclonal antibody that recognizes the
fused fluorescent proteins, anti-living colors. The human -cal-
pain large subunit was detected in the cytoplasmic, membrane,
and nuclear fractions of cells overexpressing 80K-ECFP before
and after ionomycin addition (Fig. 7A). After ionomycin treat-
ment, however, the relative amount of calpain large subunit
variant in the membrane fractions increased substantially. In
FIG. 4. Calpain subunits associate
under resting and ionomycin-acti-
vated conditions. A, fluorescence analy-
sis of COS 7 cells overexpressing large and
small calpain subunits. Fluorescence chan-
nels detected FRET (left panels) and EYFP
(right panels); phase contrast images are
shown in the middle panels. Images of the
same cell were taken under resting and
activated conditions as indicated. The
white arrows mark the observed fluores-
cence accumulation at the plasma mem-
brane. The bars represent 5 m. B, endog-
enous calpain subunits do not dissociate
under calcium-activated conditions. Cyto-
plasmic proteins extracted from wild type
LCLC 103H cells were immunoprecipi-
tated with anti-80K antibody and detected
by Western blots using anti-calpain anti-
body. Ion, cells were treated with 2 M
ionomycin for the indicated time; AC27P,
cells were preincubated with 50 M AC27P
for 1 h and then treated with 2 M ionomy-
cin for the indicated time as explained un-
der “Experimental Procedures.”
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the cytoplasmic fraction of resting cells overexpressing ECFP,
a faint band corresponding to endogenous calpain was detected,
which disappeared in activated cells because of autolysis (data
not shown). Unexpectedly, the intensity of the 80-kDa band,
corresponding to endogenous calpain, was increased in cells
overexpressing the chimeric 80K-ECFP form, compared with
wild type cells. This feature may reflect the existence of an
uncharacterized mechanism(s) of up-regulation of calpain ex-
pression by its isolated subunits, also suggested by the results
of activity measurements (Fig. 3, C and D).
The truncated variant, ECFP-DI-III, was primarily detected
in the nucleus of the cells, but it was also detectable in the
cytoplasmic fraction (Fig. 7B). After ionomycin addition, this
large subunit variant was enriched in the membrane fractions
as well. In striking contrast, ECFP-DI-IIb was localized mainly
in the nuclear and nucleolar fractions and did not relocalize
after ionophore treatment (Fig. 7C).
Domain DIII Contributes to Membrane Targeting of Cal-
pain—We had determined that chimeric variants of -calpain
that contain domain DIII were targeted to membranes upon
ionomycin-mediated activation. Considering also the proposed
membrane targeting role of DIII (14), we investigated the in-
tracellular localization of overexpressed ECFP-DIII, as well as
possible interactions between the ECFP-DIII/30K-EYFP pair
in COS 7 and LCLC 103H cells. The chimeric protein ECFP-
DIII was primarily localized in the cytoplasmic fraction, but it
was also detectable in the membrane fraction in resting cells
(Fig. 7D). After the addition of ionomycin, ECFP-DIII was
enriched in the membrane fraction (Fig. 7D).
N-terminal Helices in Domain DI Are a Putative Nuclear
Targeting Motif—Ubiquitous calpains lack stretches of posi-
tively charged residues like those of the SV40 large tumor
antigen (PKKKRKV132) (35) or the protooncogene c-myc
(PAAKRVKLD) (36), which have been repeatedly implicated as
nuclear localization signals (recently reviewed in Ref. 37). The
nuclear and nucleolar localization of the truncated ECFP-DI-
IIb variant was therefore unanticipated and provoked an in-
vestigation regarding structural elements that could be respon-
sible for this finding. With this aim, we produced five
additional chimeras derived from this variant and overex-
pressed them in LCLC 103H cells to perform subcellular local-
ization studies similar to those described above. The selected
chimeras either lack the two helices within the N-terminal DI
and the linker to DIIa (ECFP-(Ser2–Leu55)DI-IIb) or have
positively charged residues within this domain replaced by a
helix-disrupting proline within the first (ECFP-[K20P]DI-IIb)
or the second helix (ECFP-[R48P]DI-IIb). An additional charge-
mutated variant had two consecutive basic residues in domain
DIIb, Arg376 and Arg377, replaced by alanines (ECFP-
[R376A,R377A]DI-IIb). Finally, a chimera consisting of the
N-terminal helices fused to the N terminus of ECFP was con-
structed (ECFP-(Ser2–Leu55)).
To clearly document their subcellular localization, we trans-
fected these constructs into a LCLC 103H cell clone that con-
stitutively expresses histone H2A fused to EYFP (Fig. 8), ena-
bling us to study the possible influence of the mutated calpain
DI-IIb constructs on nuclear morphology and chromatin struc-
ture. Already within 24 h post-transfection the chromatin seg-
regated, with chromatin clusters appearing at the inner nu-
clear envelope. The morphology of nuclei changed dramatically
from slightly indented to multilobed “kidney” forms (Fig. 8C).
Interestingly, with the exception of the ECFP-[R376A,
R377A]DI-IIb chimera, all of the investigated variants accumu-
late in the cell nucleus (Fig. 8). Deletion of both helices, how-
ever, diminished the nuclear localization of DI-IIb. The over-
expressed chimeric proteins do not appear within organelles
(endoplasmic reticulum and vesicles). These findings suggest
an important role for the N-terminal helices of DI in the nu-
clear localization of ubiquitous calpains.
DISCUSSION
Differential Subcellular Distribution of Ubiquitous Calpains
and Calpastatin—It is becoming increasingly clear that ubiq-
FIG. 5. Intact and truncated variants of the -calpain subunits
show different subcellular localization. Confocal images of COS 7
cells overexpressing 80K-ECFP (A), 30K-EYFP (B), 80K-ECFP and
30K-EYFP (C, leakage from ECFP in EYFP has been corrected), ECFP-
DI-III (D, upper and lower panels show the whole cell or the cell
nucleus, respectively), and ECFP-DI-IIb (E, both images show the cell
nucleus). The fluorescence channel detected ECFP, except in B and C
(lower images), where EYFP has been detected. The images were taken
under resting (left column) and activated (right column) conditions.
Series of images with a distance of 50 m were taken for each channel
using single-band emission filters. Notice the increased fluorescence at
the plasma membrane of ionomycin-treated cells (white arrows in A–D),
indicating ionomycin-dependent migration to the membrane. The bars
represent 2.5 m (A), 5 m (B, left panel; C; D, upper panel; and E) and
1 m (B, right panel, and D, lower panel).
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uitous calpains play important physiological roles in vivo (see
for instance Ref. 38) and are implicated in pathological pro-
cesses such as ischemia/reperfusion injury (39, 40). The mech-
anisms of calpain assembly, activation, and regulation as well
as of cellular trafficking are therefore of considerable interest,
but they are only scarcely understood. Here we have investi-
gated the activation mechanism of ubiquitous calpains in vivo,
in particular the subcellular localization of calpain subunits
and their interaction under resting and Ca2-activated
conditions.
The addition of 2 M ionomycin increased the intracellular
Ca2 level (Fig. 3B and Ref. 27), and this moderate increase in
Ca2 concentration activates endogenous calpains in the two
cell lines studied (Fig. 3, C and D). We had previously shown
that calpain activation triggers the intrinsic apoptotic path-
way, with the first signals of caspase activity detected 3 h after
ionomycin treatment (27). The ionomycin concentration em-
ployed in the current investigation, however, did not cause
cytotoxic effects on wild type cells up to 30 min (data not
shown), the time period during which the microscopic localiza-
tion experiments were carried out. Thus, all of the observations
discussed below relate to cells before the onset of apoptosis.
We have detected a differential distribution of calpains and
calpastatin in LCLC 103H cells. Although calpains are distrib-
uted homogenously in the cytoplasm, their endogenous inhibi-
tor, calpastatin, was localized not only in the cytoplasm but
also in the cell nucleus. Of particular note, we detected iono-
mycin-induced redistribution of calpain toward membranes,
whereas the nuclear localization of calpastatin was unaffected
by the increase in intracellular Ca2 concentration. Similar
results have also been documented in proliferating culture cells
using immunofluorescent light microscopy (41). Although cal-
pains are usually viewed as cytoplasmic enzymes (Fig. 2, A and
B and Ref. 42), they have also been detected in the nucleus of
C-33A cervical carcinoma cells (41, 43). In contrast, calpastatin
is mainly localized in the nucleus (Fig. 2C; see also Ref. 41) or
in nuclear invaginations (44). Active transport of fluorescein-
labeled -calpain to the nucleus has been reported, whereas
labeled m-calpain and calpastatin were poorly transported at
best (45). Our results corroborate the variable distribution of
calpain and calpastatin in different human cells (41) but in
particular stress the physical separation between calpains and
their endogenous protein inhibitor.
FIG. 6. Co-localization of 80K-EYFP
and mem-ECFP in LCLC 103H cells.
Cells of a clone constitutively expressing
mem-ECFP were supertransfected with
80K-EYFP DNA. Fluorescence microscop-
ical analysis was performed 2 days post-
transfection in ionomycin-activated cells.
Series of images were taken in 500-nm
distances for both channels, alternatively,
subsequently processed by deconvolution
algorithms, and a color look-up table was
applied to the central image choosing
green and red for ECFP and EYFP, re-
spectively. The results are given in A and
B. These images were analyzed pixel-by-
pixel for co-localization. The result of this
analysis is shown in the scatter plot (C).
According to theory co-localization events
are located in the line x  y. An area
around this line was selected (surrounded
by the dotted line). The pixels of this area
are overlaid in yellow on the merged re-
construction of the original images (co-
localization image, D). The bars represent
5 m. Co-localization of 80K-EYFP and
mem-ECFP is very prominent in the
plasma membrane.
FIG. 7. The synaptotagmin C2-like domain of human -calpain
contributes to membrane targeting. Western blot analysis of sub-
cellular fractions of COS 7 cells overexpressing fluorescence-tagged
calpain variants 80K-ECFP (A), ECFP-DI-III (B), ECFP-DI-IIb (C), and
ECFP-DIII (D). Molecular masses of the variants (107, 87, 75, and 46
kDa, respectively) are indicated on the right. Blotted proteins were
detected with antibodies anti-DII (A) or anti-living colors (B–D). C,
cytoplasmic; M, membrane; N, nuclear; Nu, nucleolar. Upper panels,
untreated cells; lower panels (Ionomycin-activated), cells treated with 2
M ionomycin; ECFP, lysates from cells overexpressing ECFP; wt, wild
type COS 7 cells.
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Calpain Subunits Do Not Dissociate upon Activation—The
hypothesis that calpain subunits dissociate in the presence of
Ca2 has previously been tested in vitro using techniques that
cannot avoid interference from Ca2-induced aggregation phe-
nomena and/or that are probably obscured by large subunit
autolysis (1, 46). To overcome these limitations and to study for
the first time the interaction between calpain subunits in vivo,
we developed a strategy based on FRET visualization between
fluorescence-tagged calpain subunits.
First we verified that all of the ECFP fusion proteins that
contain the catalytic subunit were enzymatically active, as
shown by cleavage of the cell-permeable small peptide sub-
strate Suc-LLVY-amc (Fig. 3, C and D). These activities were
Ca2-dependent, independent of the position of the fluores-
cence label, and were reduced to the level of the endogenous
background activity in control cells preincubated with AC27P.
In our hands, the minimum active -calpain fragment com-
prises residues Ser2–Thr390 (variant DI-IIb), in agreement with
recent results (15, 47). Thus, domains DIII and DIV are dis-
pensable for calpain activity on small peptide substrates, al-
though they could play roles in enzyme localization and protein
substrate recognition, as suggested (14). Surprisingly, not only
cells overexpressing the 80K catalytic subunit alone but also
those that exclusively overexpress the 30K regulatory subunit
showed significantly higher Ca2-induced activities than wild
type and mock transfected cells. This observation points to a
previously unanticipated cross-talk between the two calpain
subunits, which results in up-regulation of the 80K by the 30K
subunit and vice versa. In this regard, we have observed that
down-regulation of the m- or -calpain catalytic subunit results
in a concomitant decrease in the levels of the regulatory sub-
unit.4 The association and stabilization of the exogenous 30K
subunit with endogenous m-/-calpain 80K subunits and vice
versa could contribute to the observed effect.
Because of their higher overexpression levels, variants 80K-
ECFP, ECFP-DI-III, ECFP-DI-IIb, ECFP-DIII, and 30K-EYFP
were selected for subunit interactions studies. We only ob-
served the FRET effect in cells co-expressing 80K-ECFP and
30K-EYFP, both under resting and Ca2-activated conditions.
This observation, together with the results of immunoprecipi-
tation experiments conducted with endogenous calpains, indi-
cates that under the given experimental conditions the sub-
units of -calpain associate not only under resting conditions
but also after activation. Domain IV seems to be indispensable
in subunit interaction because we could not detect energy
transfer between the small subunit and variants of the large
subunit lacking DIV.
These results are in agreement with several previous find-
ings in vitro: (i) Both subunits of m-/-calpain were co-precip-
itated by monoclonal antibodies directed against each single
subunit in the presence of Ca2 concentrations supporting cat-
alytic activity (12). (ii) The 80K subunit alone lacks proteinase
activity in vitro, even in the presence of Ca2, but Ca2-de-
pendent calpain activity is observed following association of the
two subunits (48). (iii) Subunit exchange does not occur in
mixtures of wild type and [C105S]80K rat m-calpain in the
presence of Ca2 (11). (iv) His-tagged rat [C105S]80K m-cal-
pain does not dissociate in the presence of Ca2 (49). (v) Nat-
ural bovine m-calpain, after irreversible inhibition with z-LLY-
CHN2, bound to immobilized casein and was eluted as a
4 S. Gil-Parrado, T. Tannenberg, L. Ruiz-Heinrich, O. Popp, and C.
Sommerhof, manuscript in preparation.
FIG. 8. N-terminal domain DI of human -calpain as nuclear targeting motif. Subcellular localization by fluorescence microscopy of
ECFP-DI-IIb variants, ECFP-(Ser2–Leu55)DI-IIb, ECFP-(Ser2–Leu55), ECFP-[K20P]DI-IIb, ECFP-[R48P]DI-IIb, and ECFP-[R376A,R377A]DI-
IIb, overexpressed in a LCLC 103H clone expressing constitutively histone H2A coupled to EYFP. A, expression pattern of the respective fragment
in the ECFP-channel (green). C, expression pattern of histone H2A in the EYFP channel (red); B, merged expression patterns (A and C). Series of
images with a distance of 200 nm were taken for each channel using single-band emission filters, processed by volume deconvolution and false
colorized (ECFP  green; EYFP  red) before merging. For the final presentation the images were contrast-enhanced by a logarithmic function to
strengthen the weak intensities in the cytoplasm. The bars represent 25 m ((Ser2–Leu55)DI-IIb, [R376A,R377A]DI-IIb), 20 m ((Ser2–Leu55),
[K20P]DI-IIb), and 13 m ([R48P]DI-IIb).
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heterodimer. (vi) Finally, the crystal structures of m-calpain
disclose large (3,000 Å2) interaction interfaces between large
and small subunits.
Despite this overwhelming body of evidence in support of the
indivisibility of the calpain heterodimer, some authors have
argued that both calpain subunits are only loosely associated
and therefore prone to dissociation. For instance, it was sug-
gested that the small subunit is exclusively needed to assist
folding of the 80K subunit. Along these lines, it has been
reported that dissociation of the large subunit from the small
subunit on exposure to Ca2 was required for the expression of
activity. Moreover, the 80K subunit shows a calcium sensitivity
identical to that of the activated form of calpain but not of the
original control calpain (50). In a recent report, Pal and co-
workers (46) discuss the results of crystallization trials con-
ducted with Ca2-activated m-calpain. Crystals were grown
that contained only the 30K subunit, whereas the large subunit
was largely found as an amorphous precipitate. However, these
results were obtained with samples maintained for large peri-
ods of time at the nonphysiologically high protein and calcium
concentrations needed for crystallization.
In contrast, the current studies were performed under cyto-
solic calcium and protein concentrations and are at odds with
the possibility of subunit dissociation in vivo. Of course, we
cannot completely exclude reversible dissociation in a time
scale much lower than the observation time and/or as a minor
process, but dissociation of calpain subunits seems to be un-
likely according to our current results and functional and struc-
tural evidence cited above.
Calpain Autolysis Products Are Not Detected in Vivo—Cal-
pain autolysis in vitro has been repeatedly reported (51, 52).
These results seeded the speculation that calpain autolysis
could contribute to the differential subcellular targeting of the
enzyme, for instance via dissociation of truncated subunits.
Antibodies raised against the N-terminal peptide of the 80K
subunit, Ser2–Gln21 (anti-peptide 80K), recognize the intact
(dissociated) large subunit in Western blots of purified calpain
and in cytoplasmic extracts (Ref. 51 and data not shown). In a
similar manner, antibodies raised against peptide Leu28–Asn33
(anti-peptide 76K) recognize 76- and 40-kDa autolysis frag-
ments in vitro. However, these anti-peptide antibodies failed to
detect the catalytic subunit or its 76/40-kDa N-terminal autol-
ysis products in living cells, both under resting and under
activated conditions. Either these antibodies are not sensitive
enough for immunocytofluorescence studies, or these frag-
ments are not produced in vivo. Alternatively, the N-terminal
region of the 80K subunit may not be accessible to these anti-
bodies within the heterodimeric calpain molecule in vivo or
may adopt a conformation(s) that differs from the one(s) recog-
nized by these antibodies. Regardless, additional experimental
evidence presented here excludes unrestricted degradation of
calpain in our current setting. We cannot rule out, however,
that autolysis at the N terminus of both subunits and other
sites could occur in other cell lines and/or in different experi-
mental settings, with concomitant dissociation of calpain sub-
units (53). This might in turn affect the differential intracellu-
lar distribution of the protease, allowing calpainolysis to take
place, e.g. in the nuclei (54–57).
Nuclear Localization of Variant DI-IIb—ECFP-DI-IIb was
almost exclusively localized in the nucleus and nucleoli (Fig.
5E). It seems unlikely that simple diffusion through nuclear
pores is responsible for this localization, because the variants
ECFP, EYFP, ECFP-DIII, and 30K-EYFP, which are of similar
size or smaller, are distributed homogenously in the cytoplasm
and nucleus.
The three-dimensional structure of m-calpain reveals a pos-
itively charged region at the N terminus of the large subunit
comprising two -helices (Fig. 1, A–E), one of which is largely
solvent-exposed in m-calpain and by analogy in all analyzed
-calpain variants containing the homologous N-terminal pep-
tide stretch (Fig. 1F). Recently, positively charged helical struc-
tures have been found responsible for nuclear targeting of
several unrelated proteins (58–60). In the light of these find-
ings and considering the lack of a consensus sequence for
nuclear localization in ubiquitous calpains, we speculated that
the -helices at the N terminus of the large subunit were
important for nuclear targeting. Indeed, deletion of both helices
from the DI-IIb chimera results in a form that is localized
mainly in the cytoplasm, whereas the helices alone were able to
direct ECFP to the cell nucleus. Our data and reports of calpain
involvement in signaling pathways (38, 61) suggest that the
nucleo-cytoplasmic distribution of calpains may be altered in
response to cell activation, differentiation, stress, or other
stimuli.
Domain III Is Critical for Membrane Targeting of CP—The
overexpressed catalytic subunit and its truncated variants,
DI-III and DIII, migrated to cell membranes under activating
conditions, in agreement with previous reports (62, 63). In
contrast, ECFP-DI-IIb did not migrate to membranes, indicat-
ing a critical role of the synaptotagmin C2-like domain DIII in
the membrane targeting mechanism of calpains. This finding is
in line with the Ca2-dependent phospholipid binding ability of
the isolated domain in vitro (20). Further, we detected relocal-
ization of the overexpressed light chain chimera 30K-EYFP
upon ionomycin addition. Remarkably, redistribution of this
form was associated with the formation of organized struc-
tures, possibly vesicles (Fig. 5B). This suggests that 30K small
subunit could oligomerize in the absence of the large subunit,
as observed by others in vitro (46).
In summary, we provide insight into the mechanisms of
calpain assembly, activation, and regulation in vivo. Our re-
sults suggest that calpain activity in the cells is regulated not
only by calpastatin but also by differential intracellular local-
ization and in particular membrane targeting of activated cal-
pain. Dissociation of its intact subunits, in contrast, appears to
play at most a secondary role in its regulation. Further, we
have begun to unravel the roles of noncatalytic domains for
calpain activity in vivo. Most interestingly, we confirm and
extend results implicating the synaptotagmin C2-like domain
III as well as the light chain domains in membrane targeting.
In addition, we identify a putative novel role for the N-terminal
domain I, regulation of nuclear localization.
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